US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
ES2873875T3
(es)
|
2004-05-13 |
2021-11-04 |
Icos Corp |
Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
|
WO2005112935A1
(en)
*
|
2004-05-13 |
2005-12-01 |
Vanderbilt University |
Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
CA2598409A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
GB2431156A
(en)
*
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
US20080032960A1
(en)
|
2006-04-04 |
2008-02-07 |
Regents Of The University Of California |
PI3 kinase antagonists
|
CN101605797A
(zh)
|
2006-11-13 |
2009-12-16 |
伊莱利利公司 |
治疗炎症疾病和癌症的噻吩并嘧啶酮
|
EP1953163A1
(en)
*
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
WO2009002553A1
(en)
*
|
2007-06-25 |
2008-12-31 |
Prolexys Pharmaceuticals, Inc. |
Methods of treating multiple myeloma and resistant cancers
|
FR2918668B1
(fr)
*
|
2007-07-09 |
2009-08-21 |
Arkema France |
Procede ameliore de preparation d'alcoxyamines issues de nitroxydes beta-phosphores.
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
EP2220089A4
(en)
*
|
2007-11-13 |
2011-10-26 |
Icos Corp |
HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE-DELTA
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
AU2014203687B2
(en)
*
|
2008-01-04 |
2016-04-14 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
MX2010007419A
(es)
*
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
RU2537549C2
(ru)
*
|
2008-01-04 |
2015-01-10 |
Интелликайн ЭлЭлСи |
Некоторые химические структуры, композиции и способы
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
US8637542B2
(en)
*
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
EP2277881A4
(en)
*
|
2008-04-18 |
2011-09-07 |
Shionogi & Co |
HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
|
CA2722326A1
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
JP5788316B2
(ja)
|
2008-07-08 |
2015-09-30 |
インテリカイン, エルエルシー |
キナーゼインヒビターおよび使用方法
|
US20110224223A1
(en)
*
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
AR072845A1
(es)
*
|
2008-07-29 |
2010-09-22 |
Boehringer Ingelheim Int |
5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
AU2009305669A1
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
SG195655A1
(en)
*
|
2008-11-13 |
2013-12-30 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
EP2397479A4
(en)
|
2009-02-12 |
2012-08-01 |
Astellas Pharma Inc |
HETERO RING DERIVATIVE
|
SG174529A1
(en)
|
2009-03-24 |
2011-10-28 |
Gilead Calistoga Llc |
Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
US8546409B2
(en)
*
|
2009-04-20 |
2013-10-01 |
Gilead Calistoga Llc |
Methods of treatment for solid tumors
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
WO2011008487A1
(en)
|
2009-06-29 |
2011-01-20 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
EP2456443A1
(en)
|
2009-07-21 |
2012-05-30 |
Gilead Calistoga LLC |
Treatment of liver disorders with pi3k inhibitors
|
JP5819831B2
(ja)
|
2009-08-17 |
2015-11-24 |
インテリカイン, エルエルシー |
複素環式化合物およびそれらの使用
|
SG179085A1
(en)
*
|
2009-09-09 |
2012-04-27 |
Avila Therapeutics Inc |
Pi3 kinase inhibitors and uses thereof
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
GB0918249D0
(en)
*
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
CN102762565A
(zh)
|
2010-02-22 |
2012-10-31 |
弗·哈夫曼-拉罗切有限公司 |
吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
|
US9193721B2
(en)
|
2010-04-14 |
2015-11-24 |
Incyte Holdings Corporation |
Fused derivatives as PI3Kδ inhibitors
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
MX2013000389A
(es)
|
2010-07-14 |
2013-03-08 |
Hoffmann La Roche |
Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
|
PH12013500236A1
(en)
|
2010-08-10 |
2017-08-09 |
Astellas Pharma Inc |
Heterocyclic compound
|
UY33337A
(es)
*
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
JP2013545749A
(ja)
*
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
EP2655374B1
(en)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
EP2678018A4
(en)
|
2011-02-23 |
2015-09-30 |
Intellikine Llc |
COMBINATION OF CHINESE HEMMER AND USES THEREOF
|
US20140213630A1
(en)
*
|
2011-03-08 |
2014-07-31 |
Thomas Diacovo |
Methods and pharmaceutical compositions for treating lymphoid malignancy
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
CN102719517B
(zh)
*
|
2011-03-29 |
2015-08-19 |
中国科学院上海药物研究所 |
一种检测化合物对人Ⅰ型PI3Ks抑制活性的方法
|
SI2705029T1
(sl)
|
2011-05-04 |
2019-03-29 |
Rhizen Pharmaceuticals S.A. |
Nove spojine kot modulatori protein-kinaz
|
CN102838601A
(zh)
*
|
2011-06-24 |
2012-12-26 |
山东亨利医药科技有限责任公司 |
选择性磷酰肌醇3-激酶δ抑制剂
|
CN102838600A
(zh)
*
|
2011-06-24 |
2012-12-26 |
山东亨利医药科技有限责任公司 |
苯基喹唑啉类PI3Kδ抑制剂
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
HK1198443A1
(en)
|
2011-07-19 |
2015-04-24 |
无限药品股份有限公司 |
Heterocyclic compounds and uses thereof
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
KR102371532B1
(ko)
|
2011-09-02 |
2022-03-07 |
인사이트 홀딩스 코포레이션 |
Pi3k 억제제로서 헤테로시클릴아민
|
EP2751112B1
(en)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
KR101995274B1
(ko)
|
2011-10-03 |
2019-07-02 |
레스피버트 리미티드 |
P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
|
WO2013082540A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Gilead Calistoga Llc |
Compositions and methods of treating a proliferative disease with a quinazolinone derivative
|
AU2012354094C1
(en)
|
2011-12-15 |
2015-10-15 |
Novartis Ag |
Use of inhibitors of the activity or function of PI3K
|
AU2015252058A1
(en)
*
|
2012-03-05 |
2015-11-19 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
WO2013134288A1
(en)
|
2012-03-05 |
2013-09-12 |
Gilead Calistoga Llc |
Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
|
HUE029420T2
(en)
|
2012-03-13 |
2017-02-28 |
Respivert Ltd |
Crystalline PI3 kinase inhibitors
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
WO2014015523A1
(en)
*
|
2012-07-27 |
2014-01-30 |
Hutchison Medipharma Limited |
Novel heteroaryl and heterocycle compounds, compositions and methods
|
SG10202003090VA
(en)
*
|
2012-08-08 |
2020-05-28 |
Kbp Biosciences Co Ltd |
PI3K δ INHIBITOR
|
CA2882134A1
(en)
*
|
2012-08-14 |
2014-02-20 |
Gilead Calistoga Llc |
Combination therapies for treating cancer
|
EP2900673A4
(en)
|
2012-09-26 |
2016-10-19 |
Univ California |
IRE1 MODULATION
|
AU2013333938A1
(en)
*
|
2012-10-16 |
2015-04-09 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
MX375194B
(es)
|
2012-11-01 |
2025-03-06 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
|
JP6434416B2
(ja)
*
|
2012-11-08 |
2018-12-05 |
ライゼン・ファーマシューティカルズ・エスアー |
PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
|
KR20150084992A
(ko)
*
|
2012-11-16 |
2015-07-22 |
머크 샤프 앤드 돔 코포레이션 |
인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제
|
WO2014100765A1
(en)
|
2012-12-21 |
2014-06-26 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
ES2685568T3
(es)
|
2012-12-21 |
2018-10-10 |
Gilead Calistoga Llc |
Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
|
WO2014112646A1
(ja)
*
|
2013-01-21 |
2014-07-24 |
国立大学法人大阪大学 |
フェノキシアルキルアミン化合物
|
WO2014128612A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
JO3279B1
(ar)
|
2013-03-15 |
2018-09-16 |
Respivert Ltd |
مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
|
US9227977B2
(en)
|
2013-03-15 |
2016-01-05 |
Respivert Ltd. |
Phosphoinositide 3-kinase inhibitors
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
CA2914284A1
(en)
|
2013-05-30 |
2014-12-04 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
NZ714710A
(en)
|
2013-06-14 |
2016-11-25 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
UY35675A
(es)
*
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015014315A1
(zh)
*
|
2013-08-01 |
2015-02-05 |
杭州普晒医药科技有限公司 |
一种抑制剂的晶型及其制备方法和用途
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
RU2675105C9
(ru)
|
2013-09-22 |
2019-01-09 |
Саншайн Лейк Фарма Ко., Лтд. |
Замещенные аминопиримидиновые соединения и способы их использования
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
EP3054953B1
(en)
|
2013-10-10 |
2020-07-01 |
Acetylon Pharmaceuticals, Inc. |
Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
|
US20160244452A1
(en)
*
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
IN2013MU03641A
(enEXAMPLES)
|
2013-11-20 |
2015-07-31 |
Cadila Healthcare Ltd |
|
JP2016537433A
(ja)
*
|
2013-11-26 |
2016-12-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
骨髄増殖性障害を処置するための治療
|
KR20160093062A
(ko)
|
2013-12-05 |
2016-08-05 |
아세르타 파마. 비.브이. |
Pi3k 억제제 및 btk 억제제의 치료적 조합
|
SI3083630T1
(sl)
|
2013-12-20 |
2019-11-29 |
Gilead Calistoga Llc |
Postopek sinteze inhibitorjev fosfatidilinozitol 3-kinaze
|
EP3083623A1
(en)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
WO2015109009A1
(en)
*
|
2014-01-15 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Carbonyl erastin analogs and their use
|
WO2015109286A1
(en)
|
2014-01-20 |
2015-07-23 |
Gilead Sciences, Inc. |
Therapies for treating cancers
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CN104817559B
(zh)
|
2014-01-30 |
2021-05-25 |
苏州泽璟生物制药股份有限公司 |
氘代喹唑啉酮化合物以及包含该化合物的药物组合物
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3110820B1
(en)
|
2014-02-28 |
2022-04-06 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
DK3116909T3
(da)
|
2014-03-14 |
2020-01-20 |
Novartis Ag |
Antistofmolekyler til lag-3 og anvendelser deraf
|
PT3119397T
(pt)
|
2014-03-19 |
2022-04-11 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
WO2015179772A1
(en)
|
2014-05-23 |
2015-11-26 |
Concert Pharmaceuticals, Inc. |
Deuterated phenylquinazolinone and phenylisoquinolinone compounds
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
TWI729644B
(zh)
|
2014-06-12 |
2021-06-01 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
EA201692267A1
(ru)
*
|
2014-06-13 |
2017-06-30 |
Джилид Сайэнс, Инк. |
Ингибиторы фосфатидилинозитол-3-киназы
|
WO2015191752A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
NZ726055A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
CN106459005A
(zh)
*
|
2014-06-13 |
2017-02-22 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|
LT3157916T
(lt)
|
2014-06-19 |
2019-04-10 |
Ariad Pharmaceuticals, Inc. |
Heteroarilo junginiai, skirti kinazės inhibavimui
|
US9944639B2
(en)
|
2014-07-04 |
2018-04-17 |
Lupin Limited |
Quinolizinone derivatives as PI3K inhibitors
|
CN104130261B
(zh)
*
|
2014-08-04 |
2016-03-02 |
山东康美乐医药科技有限公司 |
艾德利布的合成方法
|
RS63364B1
(sr)
|
2014-08-11 |
2022-07-29 |
Acerta Pharma Bv |
Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
|
TW201618773A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Btk抑制劑、pi3k抑制劑、jak-2抑制劑、及/或cdk4/6抑制劑的治療組合物
|
DK3179991T3
(da)
|
2014-08-11 |
2021-12-06 |
Acerta Pharma Bv |
Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
|
EP4578865A3
(en)
|
2014-08-12 |
2025-07-30 |
Monash University |
Lymph directing prodrugs
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
CN104262344B
(zh)
*
|
2014-08-22 |
2015-11-04 |
苏州明锐医药科技有限公司 |
艾德拉尼的制备方法
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
CN105503877A
(zh)
|
2014-09-24 |
2016-04-20 |
和记黄埔医药(上海)有限公司 |
咪唑并哒嗪类化合物及其用途
|
JP6499282B2
(ja)
|
2014-09-26 |
2019-04-10 |
ギリアード サイエンシーズ, インコーポレイテッド |
Tank結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体
|
EP3200775B1
(en)
|
2014-10-03 |
2019-11-20 |
Novartis AG |
Combination therapies
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
KR102513870B1
(ko)
|
2014-10-14 |
2023-03-23 |
노파르티스 아게 |
Pd-l1에 대한 항체 분자 및 그의 용도
|
US10214537B2
(en)
|
2014-10-22 |
2019-02-26 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl amine compounds
|
EP3209665B1
(en)
|
2014-10-22 |
2019-08-14 |
Bristol-Myers Squibb Company |
Substituted pyrrolotriazine amine compounds as pi3k inhibitors
|
SI3215518T1
(sl)
|
2014-10-29 |
2021-08-31 |
Bicyclerd Limited |
Biciklični peptidni ligandi, značilni za MT1-MMP
|
ES2879809T3
(es)
|
2014-11-01 |
2021-11-23 |
Shanghai Fochon Pharmaceutical Co Ltd |
Ciertos inhibidores de proteínas quinasas
|
EP3031808B1
(en)
|
2014-12-09 |
2018-06-27 |
ratiopharm GmbH |
Salt of idelalisib
|
WO2016097314A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Sandoz Ag |
Amorphous and crystalline forms of idelalisib and process for forming the same
|
EP3048104A1
(en)
|
2015-01-20 |
2016-07-27 |
Sandoz AG |
Amorphous and crystalline forms of idelalisib and process for forming the same
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
WO2016108206A2
(en)
*
|
2014-12-31 |
2016-07-07 |
Dr. Reddy’S Laboratories Limited |
Processes for preparation of idelalisib and intermediates thereof
|
KR101710461B1
(ko)
*
|
2015-01-16 |
2017-02-27 |
순천향대학교 산학협력단 |
키랄 2-플루오로-4-나이트로 부탄산 유도체의 제조방법
|
US9637488B2
(en)
|
2015-01-29 |
2017-05-02 |
Fuqiang Ruan |
Heterocyclic compounds as inhibitors of class I PI3KS
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
PL3262046T3
(pl)
|
2015-02-27 |
2021-05-04 |
Incyte Corporation |
Sole inhibitora pi3k i sposoby ich wytwarzania
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
LT3097102T
(lt)
|
2015-03-04 |
2018-01-25 |
Gilead Sciences, Inc. |
4,6-diamino-pirido[3,2-d]pirimidino junginiai, moduliuojantys į toll panašius receptorius
|
WO2016147206A1
(en)
*
|
2015-03-13 |
2016-09-22 |
Mylan Laboratories Limited |
Process for the preparation of amorphous idelalisib and its premix
|
US9981965B2
(en)
*
|
2015-03-31 |
2018-05-29 |
Synthon B.V. |
Process for preparing idelalisib
|
WO2016157136A1
(en)
|
2015-04-02 |
2016-10-06 |
Mylan Laboratories Ltd |
Crystalline forms of idelalisib
|
CN106146502B
(zh)
*
|
2015-04-09 |
2019-01-04 |
上海医药工业研究院 |
艾代拉里斯的合成方法及制备中间体
|
CN108033961A
(zh)
*
|
2015-04-15 |
2018-05-15 |
上海方楠生物科技有限公司 |
一种艾德力布的无定型物及其制备方法
|
CN106146352A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
Idelalisib中间体及其制备方法
|
CN106146411A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
(s)-2-(1-氨基-丙基)-5-氟-3-苯基-3h-喹唑啉-4-酮的制备方法
|
CN106146503A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
一种Idelalisib的制备方法
|
GB201506786D0
(en)
*
|
2015-04-21 |
2015-06-03 |
Ucb Biopharma Sprl |
Therapeutic use
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
CZ2015347A3
(cs)
|
2015-05-22 |
2016-11-30 |
Zentiva, K.S. |
Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava
|
CN106279171A
(zh)
*
|
2015-06-09 |
2017-01-04 |
南京安源生物医药科技有限公司 |
一种Idelalisib的制备方法
|
US20180353512A1
(en)
|
2015-06-23 |
2018-12-13 |
Gilead Sciences, Inc. |
Combination therapies for treating b-cell malignancies
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
ES2764497T3
(es)
|
2015-07-02 |
2020-06-03 |
Hoffmann La Roche |
Compuestos de benzoxazepina oxazolidinona y procedimientos de uso
|
CN111848643A
(zh)
|
2015-07-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3337506T
(pt)
|
2015-08-21 |
2021-09-24 |
Morphosys Ag |
Combinações e suas utilizações
|
CZ2015575A3
(cs)
*
|
2015-08-26 |
2017-03-08 |
Zentiva, K.S. |
Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
|
EP3344624B8
(en)
|
2015-09-02 |
2023-11-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
CN114031658A
(zh)
|
2015-09-08 |
2022-02-11 |
莫纳什大学 |
定向淋巴的前药
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
EP3355875B1
(en)
|
2015-10-01 |
2021-09-29 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
DK3364958T3
(da)
|
2015-10-23 |
2023-04-11 |
Navitor Pharm Inc |
Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
KR20180113976A
(ko)
*
|
2015-11-20 |
2018-10-17 |
센화 바이오사이언시즈 인코포레이티드 |
암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
|
HU231016B1
(hu)
*
|
2015-11-30 |
2019-11-28 |
Egis Gyógyszergyár Zrt. |
Idelalisib új polimorf és szolvát formája
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
PE20181073A1
(es)
|
2015-12-17 |
2018-07-04 |
Gilead Sciences Inc |
Compuestos inhibidores de la quinasa de union a tank
|
WO2017130221A1
(en)
*
|
2016-01-29 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
Improved process for the preparation of idelalisib
|
US20190040066A1
(en)
|
2016-02-03 |
2019-02-07 |
Lupin Limited |
Process for the preparation of phosphatidylinositol 3-kinase inhibitor
|
CN107033145B
(zh)
*
|
2016-02-04 |
2019-11-22 |
浙江大学 |
苯并噻嗪和苯并噻二嗪类化合物及制备和应用
|
EP3423057A1
(en)
|
2016-03-04 |
2019-01-09 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
WO2017156179A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
HRP20211220T1
(hr)
|
2016-03-09 |
2021-10-29 |
Raze Therapeutics Inc. |
Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
US20170306050A1
(en)
|
2016-04-08 |
2017-10-26 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN106074430A
(zh)
*
|
2016-06-13 |
2016-11-09 |
佛山市腾瑞医药科技有限公司 |
一种艾代拉利司泡腾片及其制备方法
|
PE20190510A1
(es)
|
2016-06-13 |
2019-04-10 |
I Mab |
Anticuerpos anti-pd-l1 y usos de los mismos
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
EP3471727B1
(en)
|
2016-06-21 |
2020-12-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2017221272A1
(en)
*
|
2016-06-23 |
2017-12-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of idelalisib
|
KR20190033526A
(ko)
|
2016-06-24 |
2019-03-29 |
인피니티 파마슈티칼스, 인코포레이티드 |
병용 요법
|
KR101932146B1
(ko)
*
|
2016-07-14 |
2018-12-24 |
주식회사 바이오웨이 |
Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
|
EP3272348A1
(en)
|
2016-07-21 |
2018-01-24 |
LEK Pharmaceuticals d.d. |
Pharmaceutical composition comprising idelalisib
|
JP6764017B2
(ja)
|
2016-08-04 |
2020-09-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がんの処置での使用のためのコビシスタット
|
MA46093A
(fr)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Composés modulateurs du recepteur de type toll
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
IL315777A
(en)
|
2016-10-14 |
2024-11-01 |
Takeda Pharmaceuticals Co |
Tyk2 inhibitors and uses thereof
|
CN106632337B
(zh)
*
|
2016-10-18 |
2018-11-20 |
湖北生物医药产业技术研究院有限公司 |
艾代拉里斯的晶型、药物组合物、制备方法和用途
|
CA3040286A1
(en)
*
|
2016-10-21 |
2018-04-26 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2018085069A1
(en)
|
2016-11-03 |
2018-05-11 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
US20180141939A1
(en)
|
2016-11-22 |
2018-05-24 |
Gilead Sciences, Inc. |
Solid forms of a bet inhibitor
|
WO2018102397A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
CN110603261A
(zh)
|
2016-12-23 |
2019-12-20 |
拜斯科阿迪有限公司 |
具有新型键结构的肽衍生物
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
KR20180093088A
(ko)
|
2017-01-24 |
2018-08-20 |
아이-맵 |
항-cd73 항체 및 이것의 사용
|
WO2018156895A1
(en)
|
2017-02-24 |
2018-08-30 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US10314844B2
(en)
|
2017-02-24 |
2019-06-11 |
Gilead Sciences, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
TW202515876A
(zh)
|
2017-03-08 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Tyk2抑制劑及其用途
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
US10870650B2
(en)
|
2017-04-24 |
2020-12-22 |
Natco Pharma Limited |
Process for the preparation of amorphous idelalisib
|
JP7179015B2
(ja)
|
2017-04-26 |
2022-11-28 |
ナビター ファーマシューティカルズ, インコーポレイテッド |
Sestrin-GATOR2相互座用のモジュレーターおよびその使用
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
KR20200021087A
(ko)
|
2017-06-22 |
2020-02-27 |
노파르티스 아게 |
Cd73에 대한 항체 분자 및 이의 용도
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN109111447A
(zh)
|
2017-06-23 |
2019-01-01 |
中国科学院上海药物研究所 |
7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
KR20240153614A
(ko)
|
2017-07-28 |
2024-10-23 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tyk2 억제제 및 이의 용도
|
RU2020108454A
(ru)
*
|
2017-07-31 |
2021-09-02 |
Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью Йорк |
Соединения, композиции и способы лечения t-клеточного острого лимфобластного лейкоза
|
WO2019025811A1
(en)
|
2017-08-04 |
2019-02-07 |
Bicycletx Limited |
SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
|
EP3668550A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
US20200291096A1
(en)
|
2017-08-14 |
2020-09-17 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
CA3074641A1
(en)
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
Specific akt3 activator and uses thereof
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
WO2019092253A1
(en)
|
2017-11-10 |
2019-05-16 |
Synthon B.V. |
Process for preparing idelalisib
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
KR102492115B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
WO2019136373A1
(en)
*
|
2018-01-05 |
2019-07-11 |
The Regents Of The University Of Colorado, A Body Corporate |
P110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
CN108409674A
(zh)
*
|
2018-02-09 |
2018-08-17 |
南京法恩化学有限公司 |
一种艾代拉利司中间体的制备方法
|
KR102708681B1
(ko)
|
2018-02-13 |
2024-09-26 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
KR20200131251A
(ko)
|
2018-02-15 |
2020-11-23 |
센화 바이오사이언시즈 인코포레이티드 |
퀴놀론 유사체 및 이의 염, 조성물, 및 이들의 사용 방법
|
AU2019224659A1
(en)
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
SG11202008067QA
(en)
|
2018-02-27 |
2020-09-29 |
Artax Biopharma Inc |
Chromene derivatives as inhibitors of tcr-nck interaction
|
CN108409740B
(zh)
*
|
2018-03-14 |
2020-05-08 |
盐城师范学院 |
一种艾代拉里斯制备方法
|
WO2019178596A1
(en)
|
2018-03-16 |
2019-09-19 |
Johnson Matthey Public Limited Company |
Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
US10442799B1
(en)
|
2018-04-07 |
2019-10-15 |
Fuqiang Ruan |
Heterocyclic compounds and uses thereof
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
PT4043460T
(pt)
|
2018-04-24 |
2024-09-10 |
Merck Patent Gmbh |
Compostos antiproliferação e utilizações dos mesmos
|
AU2019257651B2
(en)
|
2018-04-24 |
2023-05-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
CA3098873A1
(en)
|
2018-05-11 |
2019-11-14 |
Phosphorex, Inc. |
Microparticles and nanoparticles having negative surface charges
|
SI3793565T1
(sl)
|
2018-05-14 |
2022-04-29 |
Gilead Sciences, Inc. |
Inhibitorji MCL-1
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2021525802A
(ja)
|
2018-06-01 |
2021-09-27 |
コーネル・ユニバーシティーCornell University |
Pi3kに関連する疾患または障害に対する併用療法
|
KR20210018328A
(ko)
|
2018-06-01 |
2021-02-17 |
인사이트 코포레이션 |
Pi3k 관련 장애의 치료를 위한 투여 요법
|
DK3813946T3
(da)
|
2018-06-15 |
2024-08-19 |
Janssen Pharmaceutica Nv |
Rapamycin-analoger og anvendelser deraf
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
IL279489B1
(en)
|
2018-06-22 |
2025-06-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate comprising the peptide ligand and a pharmaceutical composition comprising the drug conjugate
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
TWI809427B
(zh)
|
2018-07-13 |
2023-07-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
CA3115088A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CN112955459A
(zh)
|
2018-10-23 |
2021-06-11 |
拜斯科技术开发有限公司 |
双环肽配体和其用途
|
CA3117336A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
CN112969505B
(zh)
|
2018-10-31 |
2023-11-14 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
DK3873903T3
(da)
|
2018-10-31 |
2024-04-02 |
Gilead Sciences Inc |
Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
BR112021010484A2
(pt)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics, Inc. |
Degradadores de irak e usos dos mesmos
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CN109593066B
(zh)
*
|
2018-12-21 |
2020-06-19 |
上海交通大学 |
一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
|
JP7699052B2
(ja)
|
2019-01-23 |
2025-06-26 |
武田薬品工業株式会社 |
Tyk2阻害剤およびその使用
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
KR102808642B1
(ko)
|
2019-03-07 |
2025-05-14 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
JP7350871B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
2’3’-環状ジヌクレオチドおよびそのプロドラッグ
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
MX2021012216A
(es)
|
2019-04-05 |
2022-01-24 |
Kymera Therapeutics Inc |
Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
MA55717A
(fr)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech Inc |
Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
SG11202113154YA
(en)
|
2019-05-31 |
2021-12-30 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
MY202182A
(en)
|
2019-06-25 |
2024-04-15 |
Gilead Sciences Inc |
Flt3l-fc fusion proteins and methods of use
|
US11795210B2
(en)
|
2019-07-16 |
2023-10-24 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
AU2020345962A1
(en)
|
2019-09-11 |
2022-03-31 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
PH12022550605A1
(en)
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
AR120096A1
(es)
|
2019-09-30 |
2022-02-02 |
Gilead Sciences Inc |
Vacunas para vhb y métodos de tratamiento de vhb
|
CA3208912A1
(en)
|
2019-10-18 |
2021-04-22 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
US11723890B2
(en)
|
2019-11-01 |
2023-08-15 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
TW202134234A
(zh)
|
2019-12-05 |
2021-09-16 |
美商奈維特製藥公司 |
雷帕黴素類似物及其用途
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADATION AGENTS AND THEIR USES
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
PT4081305T
(pt)
|
2019-12-24 |
2024-12-04 |
Gilead Sciences Inc |
Compostos moduladores da diacilglicerol quinase
|
KR20210095495A
(ko)
*
|
2020-01-23 |
2021-08-02 |
주식회사 바이오웨이 |
신규한 퀴나졸리논 화합물 및 이를 포함하는 약학적 조성물
|
CA3166908A1
(en)
|
2020-02-05 |
2021-08-12 |
Daniel Kenneth BONNER |
Lipid prodrugs of neurosteroids
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
CN115776887A
(zh)
|
2020-03-19 |
2023-03-10 |
凯麦拉医疗公司 |
Mdm2降解剂和其用途
|
CN113512042B
(zh)
*
|
2020-04-09 |
2024-06-11 |
成都赜灵生物医药科技有限公司 |
取代喹唑啉-4-酮类化合物及其制备方法和用途
|
CA3181922A1
(en)
|
2020-05-01 |
2021-11-04 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
JP2023525383A
(ja)
*
|
2020-05-16 |
2023-06-15 |
フォチョン・バイオサイエンシーズ・リミテッド |
キナーゼ阻害剤としての化合物
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
AU2021327130A1
(en)
|
2020-08-17 |
2023-03-02 |
Bicycletx Limited |
Bicycle conjugates specific for Nectin-4 and uses thereof
|
CN111840297B
(zh)
*
|
2020-08-24 |
2023-06-16 |
天津济坤医药科技有限公司 |
艾代拉里斯在制备用于治疗肝纤维化疾病的药物中的应用
|
TW202233612A
(zh)
|
2020-10-23 |
2022-09-01 |
美商林伯士科羅索公司 |
Ctps1抑制劑及其用途
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
CA3202360A1
(en)
|
2020-12-30 |
2022-07-07 |
Nello Mainolfi |
Irak degraders and uses thereof
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
CA3207049A1
(en)
|
2021-02-15 |
2022-08-18 |
Jared Gollob |
Irak4 degraders and uses thereof
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
MX2023011933A
(es)
|
2021-04-09 |
2024-01-05 |
Nimbus Clio Inc |
Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
JP2024519215A
(ja)
|
2021-05-07 |
2024-05-09 |
カイメラ セラピューティクス, インコーポレイテッド |
Cdk2分解剤およびそれらの使用
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
KR20240023629A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ピク セラピューティクス, インコーポレイテッド |
eIF4E阻害剤及びその使用
|
US12234231B2
(en)
|
2021-08-25 |
2025-02-25 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
IL314437A
(en)
|
2022-01-31 |
2024-09-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
JP2025509610A
(ja)
|
2022-03-17 |
2025-04-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
Ikarosジンクフィンガーファミリー分解剤及びその使用
|
EP4499146A1
(en)
|
2022-03-24 |
2025-02-05 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
CN117088867A
(zh)
*
|
2022-05-19 |
2023-11-21 |
杭州百诚医药科技股份有限公司 |
可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用
|
JP2025519119A
(ja)
|
2022-05-25 |
2025-06-24 |
イケナ オンコロジー, インコーポレイテッド |
Mek阻害剤及びその使用
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
AU2023317742A1
(en)
|
2022-08-02 |
2025-03-20 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
CN120019047A
(zh)
|
2022-08-02 |
2025-05-16 |
里米诺生物科学有限公司 |
杂芳基甲酰胺和相关gpr84拮抗剂及其用途
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
AR131141A1
(es)
|
2022-11-22 |
2025-02-19 |
Pic Therapeutics Inc |
Inhibidores de eif4e y usos de los mismos
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|